CJC-1295 (No DAC) / Ipamorelin Blend research peptide is supplied to qualified Canadian institutions as a characterized, co-lyophilized laboratory material for in vitro combination receptor studies. The vial pairs Modified GRF (1-29) (CJC-1295 without DAC) with ipamorelin.

In vitro, the two ligands occupy distinct receptors on short time windows: Modified GRF (1-29) at the GHRH receptor and ipamorelin at GHS-R1a. The blend is used when an experimental design requires concurrent application of a GHRH analogue and a selective ghrelin-receptor agonist, for example in pituitary-cell or transfected-receptor assays that record second-messenger or hormone-release markers. Co-lyophilization is a handling convenience; it does not create a single new mechanism. Combination results should be read against single-component controls.

The preparation is 5 mg CJC-1295 No DAC + 5 mg ipamorelin per vial. PubChem identity is not assigned to the mixture as a whole; use per-component records and the lot COA. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner. Each component is tested independently and reported at the stated HPLC purity (≥98% by HPLC per component, lot-specific) on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.